Isomorphic Labs raises USD 5bn to move AI designed drugs towards the clinic
The oversubscribed round comes six months after a USD 2.1bn Series B and will fund the move of the Alphabet backed company's first AI designed drug candidates towards clinical trials.

Isomorphic Labs, the London headquartered AI drug design company spun out of Google DeepMind in 2021, has raised USD 5 billion in a Series C round, it announced on Tuesday 17 November. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and several other new investors, and what the company called continued significant investment from Alphabet.
All existing investors also took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, according to the company release. TechCrunch reported that the new money comes on the heels of a USD 2.1 billion Series B in May.
What Isomorphic is building
Isomorphic builds on the AlphaFold protein structure work at DeepMind, which earned Demis Hassabis and John Jumper a share of the Nobel Prize in Chemistry. Its core product is a proprietary drug design engine called IsoDDE, which the company describes as a suite of foundational simulation AI models that work across multiple therapeutic areas and drug modalities. Combined with what it calls proprietary agents that reason over complex biological systems, the engine is used to design and refine candidate molecules.
The company says this work is producing positive preclinical results, both in its own oncology and immunology programmes and with partners, "setting the stage for clinical entry". TechCrunch noted that Isomorphic has struck deals with Eli Lilly, Novartis and Johnson & Johnson. Hassabis told Bloomberg that Isomorphic has more than 20 programmes under way, The Next Web reported.
Where the money goes
Isomorphic says the capital will be used to mature IsoDDE, to expand into new biology with more advanced models, to build a partner ecosystem focused on mechanistic disease biology and to build what it calls the global infrastructure for AI led bioengineering. Proceeds will also fund translational and clinical development infrastructure as the company advances its drug candidates to clinical trials.
"This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials," said Hassabis, founder and chief executive. Max Jaderberg, the company's president, said the team was making "repeatable scientific advancements" every week.
Hassabis told Bloomberg that the money will speed up the move towards clinical trials and that the company wants to expand beyond small molecules into large molecule biologics, according to The Next Web. In January he had said the company expected its first clinical trials by the end of 2026; he did not give Bloomberg an updated target, saying only that regulatory submissions were on track and that there would be more to announce in 2027.
Valuation and investors
The company did not disclose a valuation. Bloomberg had reported earlier this month that the round would value Isomorphic at about USD 50 billion, TechCrunch and The Next Web noted; that figure has not been confirmed by the company. EU-Startups put the round at about EUR 4.5 billion.
"Isomorphic Labs is building foundational technology for the future of medicine," said Konstantine Buhler, a partner at Sequoia Capital. Neil Mehta, founder and managing partner of Greenoaks, described drug discovery as "an optimization challenge of almost infinite scale". The round is Isomorphic's first since Hassabis stepped back as Google DeepMind's chief executive in August; he now chairs DeepMind and remains Isomorphic's chief executive, The Next Web reported.
Isomorphic is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
What it means for founders and investors
A USD 5 billion private round for a company that has not yet put a drug into the clinic shows how far investors are willing to go on the thesis that AI can compress drug discovery. It also concentrates capital: EU-Startups counted about EUR 148 million raised by other European AI drug discovery start ups it tracked in 2026, a small fraction of this single round. For founders in the field, the bar for differentiation rises, while partnerships with large platforms such as Isomorphic may become a more realistic route than competing head on.
The deal is also a signal for the UK, where the UK Sovereign AI Fund is among the existing backers. For more on the European AI and life sciences funding wave, see our reports on Orakl Oncology's Series A, Neurosterix's Series B and Fractile's USD 720m round.
Spotted an error? Email contact@europreneursmedia.com and we'll correct it. See our corrections policy and editorial standards.


